CN103168037A - 激酶抑制剂的合成和用途 - Google Patents

激酶抑制剂的合成和用途 Download PDF

Info

Publication number
CN103168037A
CN103168037A CN2011800421749A CN201180042174A CN103168037A CN 103168037 A CN103168037 A CN 103168037A CN 2011800421749 A CN2011800421749 A CN 2011800421749A CN 201180042174 A CN201180042174 A CN 201180042174A CN 103168037 A CN103168037 A CN 103168037A
Authority
CN
China
Prior art keywords
compound
formula
solution
solvent
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800421749A
Other languages
English (en)
Chinese (zh)
Inventor
Y.雷
C.H.贝伦斯
H-Y.李
C.L.孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grace Of Ltd By Share Ltd
Verastem Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of CN103168037A publication Critical patent/CN103168037A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN2011800421749A 2010-06-30 2011-06-28 激酶抑制剂的合成和用途 Pending CN103168037A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35994210P 2010-06-30 2010-06-30
US61/359,942 2010-06-30
PCT/US2011/042169 WO2012012139A1 (en) 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors

Publications (1)

Publication Number Publication Date
CN103168037A true CN103168037A (zh) 2013-06-19

Family

ID=45497129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800421749A Pending CN103168037A (zh) 2010-06-30 2011-06-28 激酶抑制剂的合成和用途

Country Status (10)

Country Link
US (1) US9505719B2 (https=)
EP (1) EP2588476A4 (https=)
JP (1) JP5923499B2 (https=)
CN (1) CN103168037A (https=)
AU (1) AU2011280031B2 (https=)
CA (1) CA2803005A1 (https=)
MX (1) MX343894B (https=)
NZ (1) NZ604801A (https=)
WO (1) WO2012012139A1 (https=)
ZA (1) ZA201300012B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
JP5937112B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ 選択的ｆａｋ阻害剤
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
WO2004002410A2 (en) * 2002-06-27 2004-01-08 Bristol-Myers Squibb Company 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
CN101495095A (zh) * 2006-04-28 2009-07-29 先灵公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
CN101679264A (zh) * 2007-03-16 2010-03-24 斯克里普斯研究学院 粘着斑激酶抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006005A1 (en) 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0114814A (pt) 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
ES2533258T3 (es) 2005-02-18 2015-04-08 Janssen Sciences Ireland Uc Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH
WO2007050574A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP2012753A2 (en) * 2006-04-28 2009-01-14 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
EP2046292B1 (en) 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
MX2010014057A (es) * 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.
CN102648197A (zh) 2009-08-12 2012-08-22 铂雅制药公司 促进细胞凋亡和抑制转移的方法
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
WO2004002410A2 (en) * 2002-06-27 2004-01-08 Bristol-Myers Squibb Company 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
CN101495095A (zh) * 2006-04-28 2009-07-29 先灵公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
CN101679264A (zh) * 2007-03-16 2010-03-24 斯克里普斯研究学院 粘着斑激酶抑制剂

Also Published As

Publication number Publication date
US20140235635A1 (en) 2014-08-21
JP5923499B2 (ja) 2016-05-24
CA2803005A1 (en) 2012-01-26
ZA201300012B (en) 2013-09-25
MX343894B (es) 2016-11-28
AU2011280031B2 (en) 2015-09-10
AU2011280031A1 (en) 2013-01-10
MX2012014986A (es) 2013-07-03
US9505719B2 (en) 2016-11-29
EP2588476A4 (en) 2014-07-23
NZ604801A (en) 2015-03-27
EP2588476A1 (en) 2013-05-08
JP2013529687A (ja) 2013-07-22
WO2012012139A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
KR102796586B1 (ko) 7h-피롤로[2,3-d]피리미딘 jak-억제제
EP2809660B1 (en) Macrocyclic compounds for modulating il-17
JP5774732B2 (ja) モキシフロキサシン塩酸塩の合成方法
CN102712637A (zh) 制备{4，6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3，4-b]吡啶-3-基]嘧啶-5-基}氨基甲酸甲酯的方法以及其用作医药活性物质的纯化
CN114085213B (zh) 一种arv-471的制备方法
CN103168037A (zh) 激酶抑制剂的合成和用途
CN1174192A (zh) 新的苯并咪唑,苯并噁唑和苯并噻唑化合物,制备它们的方法和含有它们的药物组合物
CN1211569A (zh) 取代的喹诺酮衍生物及含有它的药物
HU180240B (en) Process for producing new,substituted 1,3-diaryl-2-iminoimidasolidines and 2-imino-hexahydro-pyrimidines
WO2000062782A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
US6355651B1 (en) Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
CN102617601A (zh) 一种头孢地尼的制备方法
CN106692138B (zh) N-苄基咪酰胺衍生物作为多粘菌素类抗生素协同增效剂的应用
US6576764B2 (en) Synthesis and crystallization of piperazine ring-containing compounds
JP3188476B2 (ja) 両性イオン形トロバフロキサシン
EP4074719B1 (en) New-type oxazolidinone compounds and preparation method therefor
JPS5843987A (ja) 新規なジメチルホスホルアミデ−ト化合物
JP4790901B2 (ja) ４−アミノ−５−シアノイミダゾール誘導体及びその中間体の製造方法
CN110078764B (zh) 一种噁唑烷酮类化合物的制备方法
CN107721925B (zh) 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用
WO2007026376A2 (en) A novel process for preparation of highly pure crystalline hydrochlorothiazide
SK146293A3 (en) Cefalosporine salts and method of their production
US20030135043A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
CN115894198A (zh) Qulipta的关键中间体1-(2,3,6-三氟苯基)丙烷-2-酮的制备方法
KR20030076072A (ko) 신규 피리도[2,3-ｄ]피리미딘 카르보알데히드 옥심계ＰＤＥ Ⅳ 효소 저해 화합물 및 이의 제조방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: VERASTEM INC.

Free format text: FORMER OWNER: ENKATA CO., LTD.

Effective date: 20140423

Owner name: ENKATA CO., LTD.

Free format text: FORMER OWNER: PONIARD PHARMACEUTICALS INC.

Effective date: 20140423

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140423

Address after: Massachusetts, USA

Applicant after: VERASTEM, Inc.

Address before: California, USA

Applicant before: The grace of the Limited by Share Ltd.

Effective date of registration: 20140423

Address after: California, USA

Applicant after: The grace of the Limited by Share Ltd.

Address before: Washington State

Applicant before: Boniad Pharmaceutical Co.,Ltd.

RJ01 Rejection of invention patent application after publication

Application publication date: 20130619

RJ01 Rejection of invention patent application after publication